Combination therapy for extensive stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of immunotherapy (adebrelimab), a targeted drug (famitinib), and standard chemotherapy for people with extensive stage small cell lung cancer who have not had treatment before. The goal is to see if this combination works better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have extensive stage small cell lung cancer (cancer that has spread beyond one lung).
- You have not received any previous treatment for this stage of lung cancer.
- You have at least one tumor that can be measured on scans.
- You are able to take care of yourself (ECOG score 0 or 1).
- Your major organs (heart, liver, kidneys, etc.) are working normally.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (Adebelimab) combined with standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of three drugs (adebrelimab, irinotecan liposome, and famitinib) for people with extensive-stage small cell lung cancer whose disease got worse after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial is testing a new approach for extensive-stage small cell lung cancer (SCLC) that has not been treated before. It combines a high-dose chemotherapy regimen with a drug called adebrelimab (an immunotherapy) and a stem cell transplant to help your body recover. The goal is to see if this powerful combination can work better than standard treatment.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.